Cargando…

P1157: REAL-WORLD TREATMENT PATTERNS AND COMPARATIVE EFFECTIVENESS OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH MANTLE CELL LYMPHOMA

Detalles Bibliográficos
Autores principales:	Shah, B., Yang, K., Klink, A., Liu, T., Zimmerman, T., Gajra, A., Tang, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431325/ http://dx.doi.org/10.1097/01.HS9.0000847496.16686.fc

Ejemplares similares

P1110: REAL-WORLD TREATMENT PATTERNS OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) IN COMMUNITY ONCOLOGY PRACTICES IN THE UNITED STATES (US)
por: Shah, Bijal, et al.
Publicado: (2023)

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
por: Wang, Michael L., et al.
Publicado: (2023)

Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis
por: Di, Mengyang, et al.
Publicado: (2022)

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
por: Lu, Ziwen, et al.
Publicado: (2022)

P1603: EFFICACY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN ITP
por: Huang, Qiu-Sha, et al.
Publicado: (2023)

Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma
por: Axelrod, M, et al.
Publicado: (2014)

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021)

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
por: Jain, Neeraj, et al.
Publicado: (2023)

Cost-effectiveness and value of information analyses of Bruton’s tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States
por: Alrawashdh, Neda, et al.
Publicado: (2022)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect
por: Wang, Haoran, et al.
Publicado: (2022)

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)
por: Rule, Simon A., et al.
Publicado: (2019)

PB1935: CARDIOTOXICITY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITORS: A REVIEW OF REAL-WORLD OBSERVATIONAL EVIDENCE
por: Balijepalli, Chakrapani, et al.
Publicado: (2023)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: Smith, C. I. Edvard, et al.
Publicado: (2021)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Khan, Abdullah Mohammad
Publicado: (2022)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Ababneh, Obada, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023)

Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis
por: Shulga, Olga, et al.
Publicado: (2023)

The Use of Bruton’s Tyrosine Kinase Inhibitors to Treat Allergic Disorders
por: Dispenza, Melanie C.
Publicado: (2021)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies
por: Campbell, Robert, et al.
Publicado: (2018)

P1197: BRUTON’S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN RELAPSED/REFRACTORY PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF CENTRAL NERVOUS SYSTEM: A PHASE II TRIAL
por: Wang, Yali, et al.
Publicado: (2023)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor
por: Turetsky, Anna, et al.
Publicado: (2014)

P1604: IMPACT OF THROMBOPOIETIN LEVEL ON PLATELET RESPONSE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA TREATED WITH RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR
por: Kuter, David, et al.
Publicado: (2023)

Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia)
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review
por: Shen, Jing, et al.
Publicado: (2022)

Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada
por: Ball, Graeme, et al.
Publicado: (2022)

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
por: Chiron, David, et al.
Publicado: (2015)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
por: Neys, Stefan F. H., et al.
Publicado: (2021)

The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
por: Gordon, Max J., et al.
Publicado: (2021)

Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
por: von Hundelshausen, Philipp, et al.
Publicado: (2021)

Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors
por: Naik, Piyu Parth
Publicado: (2022)

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
por: Wen, Tingyu, et al.
Publicado: (2020)

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
por: Moore, Donald C., et al.
Publicado: (2021)

All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: No
por: Rotstein, Dalia L
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f7p8vt7mj11hv166mtpsq391nv